$426.11
+13.27
(+3.21%)
As of Oct 15, 2026, 1:47 AM EDT
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts May 18, 2026, the first target we tracked for AMGN.
Amgen (AMGN) is trading up at $426.11 (+3.21%) on NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on AMGN
Current price targets from 19 firms average $412, median $425, ranging from $312 to $500 — the average is 3% below the current $426. Each is tracked to its date and scored the same way a member's call is.
- BMO Capital Markets $418 → $415 by Oct 2027 Oct 12, 2026 via GuruFocus · BMO Capital Markets's track record
- Wells Fargo $415 → $430 by Oct 2027 Oct 12, 2026 via GuruFocus · Wells Fargo's track record
- Morgan Stanley $415 → $359 by Oct 2027 Oct 10, 2026 via MarketBeat · Morgan Stanley's track record
- UBS $415 → $470 by Oct 2027 Oct 10, 2026 via MarketBeat · UBS's track record
- RBC Capital Markets $406 → $430 by Oct 2027 Oct 8, 2026 via Pluang · RBC Capital Markets's track record
- Cantor Fitzgerald $406 → $440 by Oct 2027 Oct 8, 2026 via AD HOC NEWS · Cantor Fitzgerald's track record
- Truist Securities $413 → $380 by Oct 2027 Oct 7, 2026 via Investing.com Canada · Truist Securities's track record
- Cantor Fitzgerald $403 → $400 by Oct 2027 Oct 5, 2026 via Investing.com · Cantor Fitzgerald's track record
- Scotiabank $403 → $500 by Oct 2027 Oct 5, 2026 via AD HOC NEWS · Scotiabank's track record
- Scotiabank $424 → $500 by Sep 2027 Sep 29, 2026 via GuruFocus · Scotiabank's track record
- Jefferies $406 → $410 by Sep 2027 Sep 23, 2026 via Investing.com South Africa · Jefferies's track record
- UBS $380 → $430 by Sep 2027 Sep 17, 2026 via Investing.com · UBS's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Amgen revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $23.0B | $22.8B | $23.7B | $23.4B | $25.4B | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Growth (year over year) | +6.1% | −0.6% | +3.9% | −1.6% | +8.8% | +2.2% | +1.3% | +7.1% | +18.6% | +10.0% |
| Gross profit | $18.8B | $18.8B | $19.6B | $19.0B | $19.3B | $19.5B | $19.9B | $19.7B | $20.6B | $24.7B |
| Gross margin | 81.9% | 82.2% | 82.7% | 81.4% | 75.8% | 75.2% | 75.7% | 70.0% | 61.5% | 67.2% |
| Operating income | $9.79B | $9.97B | $10.3B | $9.67B | $9.14B | $7.64B | $9.57B | $7.90B | $7.26B | $9.08B |
| Operating margin | 42.6% | 43.6% | 43.2% | 41.4% | 35.9% | 29.4% | 36.3% | 28.0% | 21.7% | 24.7% |
| Net income | $7.72B | $1.98B | $8.39B | $7.84B | $7.26B | $5.89B | $6.55B | $6.72B | $4.09B | $7.71B |
| Net margin | 33.6% | 8.7% | 35.3% | 33.6% | 28.6% | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
| EPS (diluted) | $10.24 | $2.69 | $12.62 | $12.88 | $12.31 | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
| Balance sheet | ||||||||||
| Cash and equivalents | $3.24B | $3.80B | $6.95B | $6.04B | $6.27B | $7.99B | $7.63B | $10.9B | $12.0B | $9.13B |
| Total assets | $77.6B | $80.0B | $66.4B | $59.7B | $62.9B | $61.2B | $65.1B | $97.2B | $91.8B | $90.6B |
| Total liabilities | $47.8B | $54.7B | $53.9B | $50.0B | $53.5B | $54.5B | $61.5B | $90.9B | $86.0B | $81.9B |
| Long-term debt | $30.2B | $34.2B | $29.5B | $26.9B | $32.9B | $33.2B | $37.4B | $63.2B | $56.5B | $50.0B |
| Shareholders' equity | $29.9B | $25.2B | $12.5B | $9.67B | $9.41B | $6.70B | $3.66B | $6.23B | $5.88B | $8.66B |
| Cash flow | ||||||||||
| Operating cash flow | $10.4B | $11.2B | $11.3B | $9.15B | $10.5B | $9.26B | $9.72B | $8.47B | $11.5B | $9.96B |
| Capital expenditure | $738.0M | $664.0M | $738.0M | $618.0M | $608.0M | $880.0M | $936.0M | $1.11B | $1.10B | $1.86B |
| Free cash flow | $9.62B | $10.5B | $10.6B | $8.53B | $9.89B | $8.38B | $8.79B | $7.36B | $10.4B | $8.10B |
| Dividends paid | $3.00B | $3.37B | $3.51B | $3.51B | $3.75B | $4.01B | $4.20B | $4.56B | $4.83B | $5.12B |
| Share buybacks | $2.96B | $3.16B | $17.8B | $7.70B | $3.49B | $4.97B | $6.36B | $0 | $200.0M | $0 |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8.50B | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B | $10.1B |
| Growth (year over year) | +23.2% | +10.9% | +9.4% | +9.4% | +12.4% | +8.6% | +5.8% | +9.5% |
| Gross profit | $5.19B | $5.97B | $5.18B | $6.17B | $6.47B | $6.89B | $5.87B | $7.24B |
| Gross margin | 61.1% | 65.7% | 63.6% | 67.2% | 67.8% | 69.8% | 68.2% | 72.0% |
| Operating income | $2.05B | $2.31B | $1.18B | $2.66B | $2.53B | $2.72B | $2.67B | $3.51B |
| Operating margin | 24.1% | 25.4% | 14.5% | 28.9% | 26.4% | 27.6% | 30.9% | 35.0% |
| Net income | $2.83B | $627.0M | $1.73B | $1.43B | $3.22B | $1.33B | $1.82B | $2.38B |
| Net margin | 33.3% | 6.9% | 21.2% | 15.6% | 33.7% | 13.5% | 21.1% | 23.6% |
| EPS (diluted) | $5.22 | $1.17 | $3.20 | $2.65 | $5.93 | $2.45 | $3.34 | $4.37 |
| Balance sheet | ||||||||
| Cash and equivalents | $9.01B | $12.0B | $8.81B | $8.03B | $9.45B | $9.13B | $12.0B | $14.0B |
| Total assets | $90.9B | $91.8B | $89.4B | $87.9B | $90.1B | $90.6B | $92.5B | $95.6B |
| Total liabilities | $83.4B | $86.0B | $83.2B | $80.5B | $80.5B | $81.9B | $83.3B | $84.0B |
| Long-term debt | $56.9B | $56.5B | $54.0B | $53.8B | $52.4B | $50.0B | $51.9B | $51.9B |
| Shareholders' equity | $7.53B | $5.88B | $6.21B | $7.43B | $9.62B | $8.66B | $9.19B | $11.7B |
| Cash flow | ||||||||
| Operating cash flow | $3.57B | $4.77B | $1.39B | $2.28B | $4.68B | $1.60B | $2.19B | $4.00B |
| Capital expenditure | $257.0M | $371.0M | $411.0M | $369.0M | $436.0M | $642.0M | $712.0M | $513.0M |
| Free cash flow | $3.31B | $4.40B | $980.0M | $1.91B | $4.25B | $961.0M | $1.48B | $3.49B |
| Dividends paid | $1.21B | $1.21B | $1.28B | $1.28B | $1.28B | $1.28B | $1.36B | $1.36B |
From Amgen's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Amgen
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
- Headquarters
- Thousand Oaks, California From SEC filings, Oct 2026
Recent News (20)
-
Sanders Morris Harris LLC Makes New Investment in Amgen Inc. $AMGN Sanders Morris Harris LLC Makes New Investment in Amgen Inc. $AMGN MarketBeat
-
-
Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In? Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In? Yahoo Finance
-
-
AMGN Apr 2027 470.000 call (AMGN270416C00470000) Stock Historical Prices & Data - Yahoo Finance AMGN Apr 2027 470.000 call (AMGN270416C00470000) Stock Historical Prices & Data - Yahoo Finance Yahoo! Finance Canada
-
-
-
AMGN Oct 2026 405.000 put (AMGN261009P00405000) interactive stock chart AMGN Oct 2026 405.000 put (AMGN261009P00405000) interactive stock chart Yahoo Finance UK
-
First Citizens Bank & Trust Co. Purchases 6,611 Shares of Amgen Inc. $AMGN First Citizens Bank & Trust Co. Purchases 6,611 Shares of Amgen Inc. $AMGN MarketBeat
-
-
-
-
-
Amgen Inc. $AMGN Stock Purchased by Krilogy Financial LLC Amgen Inc. $AMGN Stock Purchased by Krilogy Financial LLC MarketBeat
-
-
-
-
-
-
More Health Care stocks
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- BAX Baxter International
- BDX Becton Dickinson
- BIIB Biogen
- BMY Bristol Myers Squibb